Doug Kline
Senior Scientist II Abbvie
Doug Kline received his PhD in immunology from the University of Chicago and is currently a Senior Scientist at AbbVie in Oncology Discovery. His research focuses on the interplay between tumor-intrinsic regulated cell death pathways and the subsequent host immune responses, with particular interest in understanding the role of immune cell engagement in the MOA of tumor targeting ADCs.
Seminars
- Exploring how Topo1 and Topo1-ADCs elicit immunogenic cell stress in vivo through the induction of cellular senescence
- Delineating the host immune cell requirements for Topo1-induced immunogenicity
- Identifying biomarkers of immunogenic cell stress mediated by Topo1 ADCs
Bring your burning questions to this closing panel with all the seminar day’s presenters. With all ADC pharmacology topics up for discussion, hear the speakers delve into mechanistic and PD investigation for traditional and novel ADCs to model and characterize the next wave of ADCs heading to the clinic.
Discussion Highlights Include:
- Exploring how pharmacology and mechanistic investigations can strengthen existing ADC knowledge and influence future ADC development
- Debating the therapeutic properties of conditionally active and masked ADCs to assess their ability to differentiate against traditional ADC profiles
- Discussing computational modeling and PK/PD approaches to tackle translational considerations for non-cytotoxic payload and novel format ADCs
